中奧到家(01538.HK)興訟索償2,000萬人幣獲法院受理
中奧到家(01538.HK)公布,有關集團作為買方行使認沽期權而賣方違約。儘管買方不時要求梁錫偉根據第二份補充協議支付期權價格餘額;及完成抵押餘下183個天譽花園停車位的登記程序,但梁錫偉仍未支付根據第二份補充協議結算期權價格餘額,亦未完成抵押餘下183個天譽花園停車位的登記程序,此舉構成對第二份補充協議的違約。
因此,買方已就期權價格餘額2,000萬元人民幣及所有應計利息、違約金及買方有權以拍賣或出售抵押物業(包括一套住宅及227個天譽花園停車位)的所得款項優先受償權,向中國南寧市青秀區人民法院對梁錫偉提出民事訴訟並提出索償。於上周五(14日),買方已接獲法院有關索償的受理通知。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.